Tralokinumab Shows Strong Clinical Benefit for Moderate-to-Severe Atopic Dermatitis

FOR IMMEDIATE RELEASE

HEADLINE

Tralokinumab Shows Strong Clinical Benefit for Moderate-to-Severe Atopic Dermatitis

SUMMARY

Tralokinumab (marketed in the U.S. as Adbry) is an FDA-approved biologic therapy targeting interleukin-13 (IL-13) for moderate-to-severe atopic dermatitis. New York dermatologist Dr. Dennis Porto explains why this therapy may be especially helpful for patients whose eczema has been difficult to control.

BACKGROUND: ATOPIC DERMATITIS AND ITS CHALLENGES

Atopic dermatitis, often called eczema, is a chronic inflammatory skin disease marked by intense itching, recurrent flares, barrier disruption, and a significant impact on quality of life. Many patients rely on topical steroids, calcineurin inhibitors, phototherapy, or systemic immunosuppressants — often with incomplete control, relapse, or side effects.

NEW DEVELOPMENT: WHAT IS TRALOKINUMAB

Tralokinumab is a fully human monoclonal antibody that specifically neutralizes IL-13, a cytokine central to the type-2 inflammation driving atopic dermatitis. In December 2021, the U.S. Food and Drug Administration approved tralokinumab for adults with moderate-to-severe atopic dermatitis who are not adequately controlled with topical therapies or when such therapies are inadvisable. The indication was expanded in December 2023 to include pediatric patients aged 12 years or older. An autoinjector option was added in June 2024 to improve convenience of administration.

Clinical trials have shown that tralokinumab significantly improves skin clearance, reduces itching and inflammation, and improves quality of life — offering an effective, steroid-sparing systemic therapy for patients with persistent or severe disease.

EXPERT COMMENTARY

“Atopic Dermatitis or Eczema is such a problematic disease for many of my patients, that I was thrilled when I saw these new data on Tralokinumab. As dermatologists, we really need every tool available to us as this condition can be so challenging in patients who have already tried everything. While topical steroids remain the mainstay of treatment, I’m encouraged that medications like Tralokinumab or Dupixent could change how doctors think about this condition,” said Dr. Dennis Porto, a board-certified Mohs surgeon and dermatologist in New York City.

CLINICAL SIGNIFICANCE AND OUTLOOK

For moderate-to-severe eczema patients with inadequate response to topical therapy or systemic immunosuppressants, tralokinumab now represents a well-validated, FDA-approved, targeted biologic therapy. Its IL-13–specific mechanism offers an alternative to broader immunomodulation, potentially improving safety and tolerability for long-term use.

Given its demonstrated efficacy and recent expansion to younger patients (12+), tralokinumab is likely to become a mainstay in eczema management — especially for those who have exhausted conventional options. Clinicians and patients are now able to consider biologic therapy earlier in the disease course and incorporate it into individualized, long-term treatment plans.

ABOUT DR. DENNIS PORTO

Dr. Dennis Porto, MD, MPH, FAAD, is a double board-certified Mohs micrographic surgeon and dermatologist practicing in New York City. He completed medical school at the University of Iowa, followed by a dermatology research fellowship at Harvard and advanced surgical training. Dr. Porto serves as a clinical assistant professor of dermatology at Mount Sinai and has published extensively in dermatologic surgery and inflammatory skin disease. His NYC practice integrates medical, surgical, and cosmetic dermatology with a focus on innovation, evidence-based care, and patient-centered outcomes.